Trials / Unknown
UnknownNCT05822713
A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
Randomized, Double-blind, Placebo-controlled Phase III Study of Amisulpride for IV Injection as Prophylaxis Against Post-operative Nausea and Vomiting
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 516 (estimated)
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amisulpride | 5mg/2ml |
| DRUG | Amisulpride Placebo | 2ml |
Timeline
- Start date
- 2023-04-29
- Primary completion
- 2023-08-31
- Completion
- 2023-12-31
- First posted
- 2023-04-21
- Last updated
- 2023-04-21
Source: ClinicalTrials.gov record NCT05822713. Inclusion in this directory is not an endorsement.